NeuroOne's OneRF System Shows Promise in Treating Drug-Resistant Epilepsy

NeuroOne Medical Technologies Corporation has achieved a significant milestone with the peer-reviewed publication of a clinical case series demonstrating the effectiveness of its OneRF® Ablation System. The study, published in Stereotactic and Functional Neurosurgery and accessible via PubMed, details how this FDA-cleared system—the first of its kind—enables both diagnostic and therapeutic applications using the same stereoelectroencephalography (sEEG) electrode. In four consecutive patients with drug-resistant epilepsy treated at a leading U.S. epilepsy center, the system proved safe and easily integrated into existing neurosurgical workflows, allowing treatment in operating rooms or at the patient's bedside. Real-time temperature monitoring during radiofrequency ablation ensured precise, controlled lesions while minimizing risks to surrounding brain structures, with no adverse events reported and all patients experiencing reductions in seizure burden.

The OneRF® Ablation System represents NeuroOne's first therapeutic device and third FDA 510(k)-cleared product, expanding the company's portfolio of thin-film electrode technologies. This innovation addresses a critical unmet need in neurological care by combining diagnostic brain mapping with therapeutic ablation in a single procedure, potentially reducing hospitalizations, surgical interventions, and costs. The authors highlight that this development marks a significant advancement for patients with intractable epilepsy undergoing invasive evaluation, as it provides valuable diagnostic and prognostic information to guide subsequent surgical decisions. NeuroOne estimates the combined sEEG and brain ablation market at over $200 million globally, with substantial growth potential given the large patient populations with drug-resistant neurological disorders.

For more information about NeuroOne's medical technology solutions, including the Evo® Cortical Electrodes, Evo® sEEG Electrodes, and OneRF® systems, visit nmtc1.com. The company continues to advance research in drug delivery and spinal cord stimulation, reinforcing its commitment to transforming surgical care for neurological conditions. This peer-reviewed validation underscores the system's clinical utility and safety profile, positioning NeuroOne to capture market share in a rapidly evolving medical technology landscape where minimally invasive, precision-based treatments are increasingly prioritized.